<DOC>
	<DOCNO>NCT00562978</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , find cancer cell carry tumor-killing substance without harm normal cell . Drugs use chemotherapy , etoposide cyclophosphamide , work different way kill cancer cell stop grow . Giving radiolabeled monoclonal antibody together etoposide cyclophosphamide peripheral blood stem cell transplant may effective treatment non-Hodgkin lymphoma . PURPOSE : This phase I/II trial study side effect best dose yttrium Y 90 ibritumomab tiuxetan give together etoposide cyclophosphamide follow autologous stem cell transplant see well work treat patient non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan , Etoposide , Cyclophosphamide , Autologous Stem Cell Transplant Treating Patients With Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate safety efficacy new preparative regimen yttrium Y 90 ibritumomab tiuxetan combination high-dose etoposide cyclophosphamide follow autologous stem cell transplantation ( ASCT ) treatment patient poor-risk , relapse , refractory non-Hodgkin lymphoma ( NHL ) . - To determine maximum tolerate dose yttrium Y 90 ibritumomab tiuxetan give high-dose etoposide high-dose cyclophosphamide follow ASCT patient NHL . - To perform dosimetry study estimate radiation dose deliver tumor normal organ . - To evaluate short-term long-term complication new preparative regimen . OUTLINE : This phase I does-escalation study yttrium Y 90 ibritumomab tiuxetan follow open-label phase II study . - Preparation transplantation : Peripheral blood stem cell ( PBSCs ) collect via leukapheresis . Samples analyze cytogenetic study , immunophenotyping , gene rearrangement . Patients adequate number collect CD34-positive cell ( ≥ 3 time 10^6 /kg ) proceed radioimmunotherapy . - Radioimmunotherapy : Patients receive yttrium Y 90 ibritumomab tiuxetan IV day -21 -14 . Patients undergo bone marrow biopsy dose estimation day -7 . - Chemotherapy : Patients receive etoposide IV day -4 cyclophosphamide IV 2 hour day -2 . - Transplantation : Patients undergo reinfusion PBSCs day 1 . - Growth factor therapy : Patients receive filgrastim ( G-CSF ) IV begin day 1 continue blood count recover . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy proven diagnosis low intermediategrade* nonHodgkin lymphoma ( NHL ) include follow : Follicular small cleave Follicular mix Follicular large cell Diffuse small cleave Diffuse mixed Diffuse large cell Immunoblastic ( work formulation B , C , D , E , F , G H ) NOTE : *A new classification scheme adult nonHodgkin lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . Mantle cell transform lowgrade lymphoma allow Demonstrated monoclonal CD20positive Bcell population lymph node and/or bone marrow Favorable biodistribution image dose Patient either relapse achieve complete ( CR ) partial response ( PR ) prior therapy , never respond prior therapy , poorrisk disease Sensitivity disease base 1 follow : Induction failure : patient achieve CR PR induction chemotherapy Resistant relapse : patient achieve CR PR recent standard salvage chemotherapy Sensitive relapse : patient achieve CR PR recent standard salvage chemotherapy Poorrisk disease define follow : Ageadjusted International Prognostic Index ( IPI ) High ( 3 risk factor ) HighIntermediate ( 2 risk factor ) base follow risk factor : Stage IIIIV disease Elevated serum lactate dehydrogenase level ECOG performance status 24 Patients aggressive NHL include mantle cell lymphoma require 2 different induction chemotherapy regimen achieve CR/PR Patients Bcell NHL fail achieve CR adequate induction chemotherapy regimen ( ) Patients must bone marrow aspiration biopsy within 42 day salvage chemotherapy stem cell collection show ≤ 10 % lymphomatous involvement total cellularity Normal cytogenetic study bone marrow ( prior salvage chemotherapy stem cell collection ) Cytogenetic study peripheral blood acceptable bone marrow biopsy already do show sign myelodysplastic syndrome ( MDS ) lymphoma repeat bone marrow deem unnecessary attend physician No active prior history CNS diseases No human antimouse antibody ( HAMA ) human antichimeric antibody PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 Karnofsky PS 80100 % Platelet count normal Serum creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60 mL/min FEV_1 &gt; 65 % predict DLCO ≥ 50 % predict LVEF &gt; 50 % ECHO MUGA scan Bilirubin ≤ 1.5 time normal SGOT SGPT ≤ 2 time normal HIV antibodynegative No prior malignancy except adequately treat basal cell squamous cell skin cancer , adequately treat noninvasive carcinoma , cancer patient diseasefree least five year No active evidence hepatitis B C infection No hepatitis B surface antigen positivity No history alcohol abuse Body weight ≤ 250 pound PRIOR CONCURRENT THERAPY : See Disease Characteristics Patients receive involved field external beam therapy area exclude lung , heart , liver kidney allow , evaluated casebycase basis Patients must recover last therapy least four week prior radiation chemotherapy No prior radioimmunotherapy No prior bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
</DOC>